胶质瘤细胞与巨噬细胞融合获得高SLC7A5表达促进恶性进展
本研究探讨巨噬细胞与胶质瘤细胞融合形成的杂交细胞的特征与功能。单细胞测序及人胶质瘤标本证实存在双阳性杂交细胞,体外融合模型显示其染色体含量增加、增殖与侵袭显著增强,SLC7A5是关键驱动基因,杂交细胞对SLC7A5抑制剂JPH203更敏感。
要点
- 巨噬细胞-胶质瘤杂交细胞在体内外均被证实存在,增殖和侵袭能力显著增强。
- 巨噬细胞来源基因SLC7A5是杂交细胞恶性表型的关键驱动因素。
- 杂交细胞对SLC7A5抑制剂JPH203的敏感性高于亲本细胞,提示潜在治疗靶点。
核心结论
- 与巨噬细胞融合使胶质瘤细胞获得增强的恶性表型,表现为增殖和侵袭增加,该过程由巨噬细胞来源基因SLC7A5驱动。
- 靶向SLC7A5是胶质瘤有前景的新型治疗策略。
研究设计与样本
- 研究采用单细胞测序数据和人胶质瘤标本确认巨噬细胞-胶质瘤双阳性细胞的存在。
- 建立体外融合模型,用流式细胞术分析杂交细胞,并通过功能实验评估增殖和侵袭能力。
- 机制研究聚焦巨噬细胞来源基因SLC7A5,并用SLC7A5抑制剂JPH203测试药物敏感性。
主要发现
- 巨噬细胞-胶质瘤杂交细胞在体内和体外均被识别。
- 杂交细胞染色体含量增加,增殖和侵袭能力显著增强。
- SLC7A5被确定为该恶性表型的关键驱动因子。
- 与亲本细胞相比,杂交细胞对SLC7A5抑制剂JPH203表现出更高的敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the characteristics and functional role of macrophage(MΦ)-glioma hybrid cells formed through cell fusion, and to explore the underlying mechanisms and potential therapeutic targets in glioma progression. METHODS: The presence of MΦ-glioma double-positive cells was confirmed using single-cell sequencing data and human glioma specimens. An in vitro fusion model was established, and hybrid cells were analyzed for flow cytometry. Functional assays assessed proliferation and invasion capabilities. Mechanistic studies focused on the role of SLC7A5, a MΦ-derived gene, and drug sensitivity was tested using the SLC7A5 inhibitor JPH203. RESULTS: MΦ-glioma hybrid cells were identified both in vivo and in vitro. These hybrids exhibited increased chromosomal content and demonstrated significantly enhanced proliferation and invasion. Mechanistically, SLC7A5 was identified as a key driver of this malignant phenotype. Furthermore, hybrid cells showed greater sensitivity to the SLC7A5 inhibitor JPH203 compared to parental cells. CONCLUSION: Fusion with MΦs confers enhanced malignancy to glioma cells, characterized by increased proliferation and invasion, which is promoted by the MΦ-derived gene SLC7A5. Targeting SLC7A5 represents a promising novel therapeutic strategy for glioma.
引用
- Hu Y, Liu F, Mi R, et al. Glioma cells achieve malignant progression by fusion with macrophages to gain high SLC7A5 expression. J Neurooncol. 2025. PMID: 41402663. doi:10.1007/s11060-025-05382-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。